Increased rates of macropinocytosis in KrasG12D MEFs and KRAS-mutant human cancer cells were significantly attenuated by knockdown of KRAS or treatment with a pharmacological inhibitor of macropinocytosis, 5-(N-ethyl-N-isopropyl)-amiloride (EIPA) (Figure 1D,E). Here, KRAS is linked to cancer.